Free shipping on all orders over $ 500

CID5721353

Cat. No. M9248

All AbMole products are for research use only, cannot be used for human consumption.

CID5721353 Structure
Synonym:

BCL6 Inhibitor

Size Price Availability Quantity
10mM*1mL in DMSO USD 80 In stock
5mg USD 75 In stock
10mg USD 110 In stock
25mg USD 195 In stock
50mg USD 295 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

CID5721353 specifically inhibits BCL6 repressor activity. CID5721353 disrupts BCL6 transcriptional complexes and reactivates BCL6 target genes. CID5721353 can specifically kill primary human DLBCL cells. 79% BCL6-positive cases display greater than 25% loss of viability in response to CID5721353 at 125 or 250 μM.

In vivo, 107OCI-Ly7 cells are injected into the right flank of 10 SCID mice and allowed to form tumors. Once tumors reach ~1.5 grams, animals are injected IP with a single dose of 50 mg/kg of CID5721353 in 10% DMSO or vehicle (10% DMSO) and sacrificed at 0.5, 1, 1.5, 3, 6, 12 and 24 hours after CID5721353 administration. Blood and tumors are harvested. Quantitative HPLC/MS analysis of the serum shows that CID5721353 levels peak (to 55 μg/mL, which is equivalent to a 122 μM concentration) one hour after the IP injection. CID5721353 also reaches its highest peak (24.5 ng/mg) at the 1-hour time point in the tumors, and after a sharp decline in levels, decreases gradually over 24 hours.

Chemical Information
Molecular Weight 457.28
Formula C15H9BrN2O6S2
CAS Number 301356-95-6
Solubility (25°C) DMSO: ≥ 40 mg/mL
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
References

[1] Cerchietti LC, et al. Cancer Cell. A small-molecule inhibitor of BCL6 kills DLBCL cells in vitro and in vivo.

Related Bcl-2 Products
ABT-263

ABT-263 (Navitoclax) is a potent, orally bioavailable inhibitor of the antiapoptotic Bcl-2 family members Bcl-2, Bcl-x (L), and Bcl-w.

ABT-737

ABT-737 is a potent and selective inhibitor of B-cell lymphoma-2 (BCL-2) family proteins, in small cell lung cancer.

AT-101

AT-101 (R-(-)-gossypol acetic acid) is a pan small molecule inhibitor of Bcl-2, Bcl-xL, and Mcl-1.

ABT-199

ABT-199 (Venetoclax) is a highly potent, orally bioavailable and BCL-2 inhibitor. ABT-199 is the first inhibitor targeting Bcl-2 and PPI.

TW-37

TW-37 is a novel nonpeptide inhibitor to recombinant Bcl-2, Bcl-xL and Mcl-1 with Ki of 0.29 μM, 1.11 μM and 0.26 μM, respectively.

  Catalog
Abmole Inhibitor Catalog




Keywords: CID5721353, BCL6 Inhibitor supplier, Bcl-2, inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2026 AbMole BioScience. All Rights Reserved.